Because of the high expression of DR4 and DR5 in primary AML cells, as well as in AML cell lines, we assumed that a gene therapy approach that used TRAIL-coated adenovirus as an oncolytic vector might result in therapeutic efficacy by inducing apoptosis. The gene discussed is TNFSF10; the disease is acute myeloid leukemia.